9.52
前日終値:
$12.32
開ける:
$9.145
24時間の取引高:
25.34M
Relative Volume:
3.40
時価総額:
$1.02B
収益:
$52.86M
当期純損益:
$-480.19M
株価収益率:
-2.0299
EPS:
-4.6899
ネットキャッシュフロー:
$-421.82M
1週間 パフォーマンス:
-24.56%
1か月 パフォーマンス:
-53.42%
6か月 パフォーマンス:
+30.59%
1年 パフォーマンス:
-40.50%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
NTLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc
|
9.52 | 1.32B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-28 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
| 2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Sell |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-06-16 | 開始されました | BofA Securities | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-02-18 | 開始されました | William Blair | Outperform |
| 2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 開始されました | Cowen | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
| 2021-10-05 | 開始されました | Guggenheim | Buy |
| 2021-09-24 | 開始されました | Stifel | Buy |
| 2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 開始されました | Truist | Buy |
| 2020-10-14 | 開始されました | Wells Fargo | Overweight |
| 2020-09-18 | 開始されました | Goldman | Buy |
| 2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-10 | 開始されました | ROTH Capital | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-10-29 | 開始されました | Credit Suisse | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Mkt Perform |
| 2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-11-01 | 繰り返されました | Jefferies | Buy |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Intellia Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
NTLA: Analyst Chardan Capital Lowers Price Target; Maintains Buy Rating | NTLA Stock News - GuruFocus
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Wells Fargo Lowers PT on Intellia Therapeutics (NTLA), Maintains Rating | NTLA Stock News - GuruFocus
NTLA: RBC Capital Maintains Rating, Lowers Price Target by 36% | - GuruFocus
Intellia Therapeutics patient death prompts FDA clinical hold on CRISPR heart disease trials - The Business Journals
RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating - MarketScreener
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial - Genetic Engineering and Biotechnology News
Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers - BioPharma Dive
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year - TipRanks
Intellia Therapeutics Says a Patient Died in Gene Editing Trial - Barron's
Wedbush Maintains NTLA Rating, Lowers Price Target to $7 | NTLA Stock News - GuruFocus
NTLA’s Trials Pause: A Trigger for Stock Decline? - StocksToTrade
Intellia Tumbles After Patient Dies Following Crispr Treatment - Bloomberg.com
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - TradingView
Intellia Therapeutics stock price target lowered to $9 at RBC after patient death - Investing.com Canada
NTLA's Analyst Rating Maintained but Price Target Lowered | NTLA Stock News - GuruFocus
Patient with liver damage in Intellia trial dies - statnews.com
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Reports Strong Revenue Growth and S - GuruFocus
Is It Too Late to Buy NTLA? - timothysykes.com
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - AOL.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Intellia shares fall after hospitalised CRISPR patient dies - pharmaphorum
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate - BioSpace
Intellia Therapeutics (NTLA) Shares Plunge After Phase 3 Trial S - GuruFocus
JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12 - MarketScreener
JP Morgan Downgrades Intellia Therapeutics (NTLA) with Lower Pri - GuruFocus
Intellia stock plunges after patient death (NTLA:NASDAQ) - Seeking Alpha
Chart overlay techniques for tracking Intellia Therapeutics Inc.Forecast Cut & High Win Rate Trade Alerts - newser.com
Patient hospitalised after receiving Intellia's CRISPR therapy dies - FirstWord Pharma
Intellia Therapeutics (NTLA) Faces Setback with FDA Hold on Key Trials - GuruFocus
Intellia Therapeutics stock rating maintained at Neutral by Baird - Investing.com India
Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty - TipRanks
Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan - TipRanks
Transcript : Intellia Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Patient dies after receiving Intellia's CRISPR therapy - Fierce Biotech
JPMorgan downgrades Intellia Therapeutics stock on liver toxicity concerns - Investing.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Earnings Summary & Precise Buy Zone Identification - newser.com
Intellia Trims Losses And Edges Toward Major Drug Launch - Finimize
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury - Endpoints News
Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback - TipRanks
Intellia Therapeutics Third Quarter 2025 Financial Results Call - Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Intellia Therapeutics Q3 2025 Earnings: EPS of -$0.99 and Revenue of $15.19 Million Meet Estimates - GuruFocus
Intellia Therapeutics Inc earnings beat by $0.09, revenue fell short of estimates - Investing.com
Intellia Q3 net loss narrows - MarketScreener
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics
Intellia (NASDAQ: NTLA) completes HAELO Phase 3 enrollment; topline mid-2026 - Stock Titan
Will Intellia Therapeutics Inc. (38I) stock recover faster than industry2025 Volatility Report & AI Powered Market Trend Analysis - newser.com
Does Intellia Therapeutics Inc. stock trade at a discount to peersWeekly Trade Summary & High Accuracy Investment Signals - fcp.pa.gov.br
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):